
Rina-S Displays Early Efficacy in Advanced Ovarian Cancer
Preliminary activity observed with the novel folate receptor alpha [FRα]-directed antibody-drug conjugate rinatabart sesutecan (Rina-S) among patients with advanced ovarian cancer in the phase 1/2 RAINFOL-01 study (NCT05579366) has stirred up …